|SGLT2 Inhibitor Diabetes Drug List|
Issue: Increased risk of leg & foot amputations after Invokana or Invokamet usage
May 2017: FDA Confirms Increased Risk of Leg & Foot Amputations with Invokana or Invokamet Use
In May 2017 the U.S. Food and Drug Adminstration issued a heightened Invokana warning confirming earlier studies that “the type 2 diabetes medication canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.” The FDA further noted it is requiring new warnings, including its most prominent Boxed Warning, to be added to all Invokana and Invokamet drug labels to warn patients about these serious risks.
The FDA further advised all patients taking Invokana or Invokamet to notify their health care professionals immediately if they develop “any new pain or tenderness, sores or ulcers, or infections in the legs or feet.” The FDA also advised warned doctors before prescribing Invokana/Invokamet to consider all factors that might predispose patients to a risk of amputations, which risk could be doubled by the use of Invokana or Invokamet.
Lieff Cabraser has successfully represented tens of thousands of clients in personal injury and dangerous prescription drug cases across America. U.S. News, Best Lawyers, and the National Law Journal have all recognized us as one of the top plaintiffs’ law firms in the nation.
Contact National Drug Injury Lawyers
If you have had a leg or foot amputation you think may be related to your use of Invokana or Invokamet, please contact us today by completing the contact form below or by calling us toll-free at 1 800-541-7358 and ask to speak to attorney Sarah London.
What are SGLT2 Inhibitors like Invokana or Invokamet?
SGLT2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with Type 2 diabetes. SGLT2 is an abbreviation for sodium-glucose cotransporter-2.
SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine.
The active ingredient of SGLT2 inibitors is canagliflozin, dapagliflozin, or empagliflozin. These medicines are available as single-ingredient products sold under the brand names:
- Farxiga, and
The active ingredients of SGLT2 inhibitors are also used in combination with other diabetes medicines. These medications are:
- Xigduo, and
What Does the FDA Say About Amputations Caused by Invokana or Invokamet?
The FDA has reviewed data from two large clinical trials of type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) and has concluded that these drugs cause a doubled risk of foot or leg amputation in patients. The data “showed that toe, leg, and foot amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo.”
The FDA urges patients to contact their doctors right away if they experience any new symptoms that might relate to conditions requiring amputation (including new pain, soreness, or ulceration or infection) and has urged health care professionals and patients to report side effects involving SGLT2 inhibitors to the FDA MedWatch program.
What are my legal rights?
Manufacturers of prescription drugs have a duty to patients to produce safe products and to warn patients and doctors of all serious side effects from their medications.
The law in most states provides several personal injury claims for patients who have been seriously injured by a prescription drug with dangerous and undisclosed side effects.
These claims include strict liability for a defective product, breach of warranty, negligence, and misrepresentation. Damages sought against pharmaceutical companies for dangerous drug side effects and injuries include:
- Physical pain and suffering, mental anguish and physical impairment;
- Medical expenses, past and future; and
- Loss of earnings and/or earning capacity.
In the case of a patient’s death, the family of the victim may file a wrongful death action and seek damages.
This website is not intended to provide medical advice. The FDA states that patients should not stop or change their diabetes medicines without talking to their physician. If you have new pain or tenderness, sores or ulcers, or infections in your legs or feet, talk to your physician immediately.
Invokana is a registered trademark of Janssen Pharmaceuticals, Inc. Farxiga is a registered trademark of AstraZeneca Pharmaceuticals LP. Jardiance is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc. Invokamet is a registered trademark of Janssen Pharmaceuticals, Inc. Xigduo is a registered trademark of AstraZeneca Pharmaceuticals LP. Glyxambi is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc. The use of these trademarks is solely for product identification and informational purposes. None of these companies are affiliated with this website, neither do they have any affiliation with Lieff Cabraser. Nothing on this site has been authorized or approved by any of these companies.